| Literature DB >> 15924223 |
Byoung-Kuk Na1, Hyeong-Woo Lee, Sung-Ung Moon, Tae-Suk In, Khin Lin, Maung Maung, Gyung-Tae Chung, Jong-Koo Lee, Tong-Soo Kim, Yoon Kong.
Abstract
Dihydrofolate reductase (DHFR; EC1.5.1.3) is a known target enzyme for antifolate agents, which are used as alternative chemotherapeutics for chloroquine-resistant malaria. Mutations in the dhfr gene of Plasmodium vivax are thought to be associated with resistance to the antifolate drugs. In this study, we have analyzed genetic variations in the dhfr genes of clinical isolates of P. vivax (n=21) in Myanmar, to monitor antifolate resistance in this country. Sequence variations within the entire dhfr gene were highly restricted to codons from 57 to 117, and the GGDN tandem repeat region. Double (S58R and S117N/T) or quadruple mutations (F57L/I, S58R, T61M, and S117N/T), which may be closely related to the drug resistance, were recognized in most of the isolates (20/21 cases). Our results suggest that antifolate-resistant P. vivax is becoming widespread in Myanmar, as it also is in the neighboring countries in Southeast Asia. It appears that the drug resistance situation may be worsening in the country.Entities:
Mesh:
Substances:
Year: 2005 PMID: 15924223 DOI: 10.1007/s00436-005-1364-0
Source DB: PubMed Journal: Parasitol Res ISSN: 0932-0113 Impact factor: 2.289